Stabilized radiolabeled anti-CD45 immunoglobulin compositions
AssigneeActinium Pharmaceuticals, Inc.
InventorsKaushik Dave, Shubh Sharma
Life of this patent
Estimating the term…
Abstract
Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radiotherapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.
Claims11
An aqueous composition comprising (i) an 131I-labeled anti-CD45 IgG monoclonal antibody, and (ii) 0.5% to 5.0% (w/v) of an excipient selected from the group consisting of ascorbic acid, polyvinylpyrrolidone (PVP), human serum albumin (HSA), a water-soluble salt of HSA, and mixtures thereof, wherein the 131I-labeled anti-CD45 IgG monoclonal antibody is a BC8 antibody comprising a heavy chain having the amino acid sequence as set forth in SEQ ID NO:14.
An aqueous pharmaceutical composition comprising:
- an 131I-labeled BC8 antibody;
- and
- a pharmaceutically acceptable carrier, wherein the 131I-labeled BC8 antibody comprises a heavy chain having the amino acid sequence as set forth in SEQ ID NO:14.
Dependencies are inferred from the claim text.